Apo E polymorphism and coronary heart disease;Polimorfismo de la apolipoproteína E y enfermedad coronaria

Medicina Clinica

Volumn 116, Issue 18, 2001, Pages 681-685

  Peña, Rocío ^a   Mostaza, José M ^a   Lahoz, Carlos ^a   Jiménez, Javier ^b   Subirats, Enric ^c   Pinto, Xavier ^d   Taboada, Manuel ^e   López Pastor, Ángela ^a  

^a HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

^b INSTITUTO DE SALUD CARLOS III   (Spain)

^c Hospital de Puigcerdà   (Spain)

^d HOSPITAL UNIVERSITARI DE BELLVITGE   (Spain)

^e Centro de Salud de Fuencarral   (Spain)

Author keywords

Apo E genotype; Apolipoprotein E; Cardiovascular disease

Indexed keywords

APOLIPOPROTEIN E;

ARTICLE; BLOOD; CORONARY ARTERY DISEASE; FEMALE; GENETIC POLYMORPHISM; GENETICS; HUMAN; HYPERCHOLESTEROLEMIA; MALE; MIDDLE AGED;

APOLIPOPROTEINS E; CORONARY DISEASE; FEMALE; HUMANS; HYPERCHOLESTEROLEMIA; MALE; MIDDLE AGED; POLYMORPHISM, GENETIC;

EID: 0038967854     PISSN: 00257753     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0025-7753(01)71952-5     Document Type: Article

References (35)

1. Lahoz C, Ordovas JM. Apo E: lípidos plasmáticos, cardiopatía isquémica y enfermedad de Alzheimer. Med Clin (Barc) 1997; 109: 31-36.
2. Lahoz C, Mostaza JM. Marcadores genéticos asociados a cardiopatía isquémica. Med Clin (Barc) 1999; 113: 463-470.
3. Tiret L, De Knijff P, Menzel HJ, Ehnholm C, Nicaud V, Havekes LM. Apo E polymorphism and predisposition to coronary heart disease in youths of different European populations. The EARS Study European Atherosclerosis Research Study. Arterioscler Thromb 1994; 14: 1617-1624.
4. Luc G, Bard JM, Arveiler D, Evans A, Cambou JP, Bingham A et al. Impact of apolipoprotein E polymorphism on lipoproteins and risk of myocardial infarction. The ECTIM Study. Arterioscler Thromb 1994; 14: 1412-1419.
5. Gerdes LU, Klausen IC, Sihm I, Faergeman O. Apolipoprotein E polymorphism in a Danish population compared to findings in 45 other study populations around the world. Genet Epidemiol 1992; 9: 155-167.
6. Schiele F, De Bacquer D, Vincent-Viry M, Beisiegel U, Ehnholm C, Evans A et al. Apolipoprotein E serum concentration and polymorphism in six european countries: the ApoEurope project. Atherosclerosis 2000; 152: 475-488.
7. Nieminen MS, Mattila KJ, Aalto-Setala K, Kuusi T, Kontula K, Kauppinen-Makelin R et al. Lipoproteins and their genetic variation in subjects with and without angiographically verified coronary artery disease. Arterioscler Thromb 1992; 12: 58-69.
8. Wilson PW, Myers RH, Larson MG, Ordovas JM, Wolf PA, Schaefer EJ. Apolipoprotein E alleles, dyslipidemia, and coronary heart disease. The Framingham Offspring Study. JAMA 1994; 272: 1666-1671.
9. Wang XL, McCredie RM, Wilcken DE. Polymorphisms of the apolipoprotein E gene and severity of coronary artery disease defined by angiography. Arterioscler Thromb Vasc Biol 1995; 15: 1030-1034.
10. Hixson JE. Apolipoprotein E polymorphisms affect atherosclerosis in young males. Pathobiological Determinants of Atherosclerosis in Youth (PDAY) Research Group. Arterioscler Thromb 1991; 11: 1237-1244.
11. Eichner JE, Kuller LH, Orchard TJ, Grandits GA, McCallum LM, Ferrell RE et al. Relation of apolipoprotein E phenotype to myocardial infarction and mortality from coronary artery disease. Am J Cardiol 1993; 71: 160-165.
12. Stengard JH, Zerba KE, Pekkanen J, Ehnholm C, Nissinen A, Sing CF. Apolipoprotein E polymorphism predicts death from coronary heart disease in a longitudinal study of elderly Finnish men. Circulation 1995; 91: 265-269.
13. Gerdes LU, Gerdes C, Kervinen K, Savolainen M, Klausen IC, Hansen PS et al. The apolipoprotein epsilon4 allele determines prognosis and the effect on prognosis of simvastatin in survivors of myocardial infarction: a substudy of the Scandinavian simvastatin survival study. Circulation 2000; 101: 1366-1371.
14. Wilson PW, Schaefer EJ, Larson MG, Ordovas JM. Apolipoprotein E alleles and risk of coronary disease. A meta-analysis. Arterioscler Thromb Vasc Biol 1996; 16: 1250-1255.
15. Stengard JH, Weiss KM, Sing CF. An ecological study of association between coronary heart disease mortality rates in men and the relative frequencies of common allelic variations in the gene coding for apolipoprotein E. Hum Genet 1998; 103: 234-241.
16. De Knijff P, Havekes LM. Apolipoprotein E as a risk factor for coronary heart disease: a genetic and molecular biology approach. Curr Opin Lipidol 1996; 7: 59-63.
17. Anonymous. Summary of the second report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel II). JAMA 1993; 269: 3015-3023.
18. 2. Clin Chem 1983; 29: 2026-2030.
19. Lahoz C, Osgood D, Wilson PW, Schaefer EJ, Ordovas JM. Frequency of phenotype-genotype discrepancies at the apolipoprotein E locus in a large population study. Clin Chem 1996; 42: 1817-1823.
20. Joven J, Simo JM, Vilella E, Camps J, Masana L, De Febrer G et al. Lipoprotein(a) and the significance of the association between platelet glycoprotein IIIa polymorphisms and the risk of premature myocardial infarction Atherosclerosis 1998; 140: 155-159.
21. Gómez-Coronado D, Álvarez JJ, Entrala A, Olmos JM, Herrera E, Lasuncion MA. Apolipoprotein E polymorphism in men and women from a Spanish population: allele frequencies and influence on plasma lipids and apolipoproteins. Atherosclerosis 1999; 147: 167-176.
22. Muros M, Rodríguez-Ferrer C. Apolipoprotein E polymorphism influence on lipids, apolipoproteins and Lp(a) in a Spanish population underexpressing apo E4. Atherosclerosis 1996; 121: 13-21.
23. Álvarez V, Álvarez R, Pena J, Lahcz CH, Martínez C, Menéndez-Guisasola L et al. Frecuencia del alelo APOE-4 en la enfermedad de Alzheimer en la población asturiana y su variación con la edad. Med Clin (Barc) 1999; 113: 441-443.
24. Pérez Estrada E, Escolar JL, Valdivielso P, Andrade R, Pérez-Estrada Cornejo M, González Santos P. Fenotipos de apoproteina E. Estudio er la población de Málaga. Rev Clin Esp 1990; 187: 3-5.
25. Valveny N, Esteban E, Kandil M, Moral P. APO E polymorphism in Spanish and Moroccan populations. Clin Genet 1997; 51: 354-356.
26. Corella D, Gaillen M, Portoles O, Sabater A, Cortina S, Folch J et al. Polimorfismos en el gen de la apoproteina E y riesgo de hipercolesterolemia: un estu dio de casos y controles en una población laboral de Valencia. Med Clin (Barc) 2000; 115: 170-175.
27. López-Miranda J, Ordovas JM, Mata P, Lichtenstein AH, Clevidence B, Judd JT et al. Effect of apolipoprotein E phenotype on diet-induced lowering of plasma low density lipoprotein cholesterol. J Lipid Res 1994; 35: 1965-1975.
28. Corbo RM, Vilarde T, Ruggeri M, Gemma AT, Scacchi R. Apolipoprotein E genotype and plasma levels in coronary artery disease. A case-control study in the Italian population. Clin Biochem 1999; 32: 217-222.
29. Scaglione L, Bergerone S, Gambino R, Imazio M, Macchia G, Cravelto A et al. Role of lipid, apolipoprotein levels and apolipoprotein E genotype in young Italian patients with myocardial infarction. Nutr Metab Cardiovasc Dis 1999; 9: 118-124.
30. Corbo RM, Vilardo T, Mantuano E, Ruggeri M, Gemma AT, Scacchi R. Apolipoproteins B and E, and angiotensin l-converting enzyme (ACE) genetic polymorphisms in Italian women with coronary artery disease (CAD) and their relationships with plasma lipid and apolipoprotein levels. Clin Genet 1997; 52: 77-82.
31. Boemi M, Sirolla C, Amadio L, Fumelli P, Pornetta D, James RW. Apolipoprotein E polymorphism as a risk factor for vascular disease in diabetic patients. Diabetes Care 1995; 18: 504-508.
32. Bercedo-Sanz A, González-Lamuno D, Malaga S, García-Fuentes M. Impact of ApoE4 allele on total cholesterol levels of children in northern Spain. Clin Genet 1999; 55: 69-70.
33. Curtiss LK. ApoE in atherosclerosis: a protein with multiple hats. Arterioscler Thromb Vasc Biol 2000; 20: 1852-1853.
34. Ordovas JM, López Miranda J, Pérez Jiménez F, Rodriguez C, Park JS, Cole T et al. Effect of apolipoprotein E and A-IV phenotypes on the low density lipoprotein response to HMG CoA reductase inhibitor therapy. Atherosclerosis 1995; 113: 157-166.
35. Carmena R, Roederer G, Mailloux H, Lusster Cacan S, Davignon J. The response to lovastatin treatment in patients with heterozygous familial hypercholesterolemia is moculated by apolipoprotein E polymorphism. Metabolism 1993; 42: 895-901.